Join the July 16th webinar hosted by EUPHORIA Co-ordinator iThera Medical, 3:00-4:00 BST.
Hear Dr Guido Giacalone, Head of the Department of Lymphatic Surgery at AZ Sint-Maarten (Mechelen, Belgium) outline his work in the field and the use of MSOT for preoperative mapping of lymphatic and blood vessels.
Particular topics covered include:
– An overview of the field of lymphatic surgery and the need for high resolution, fast and accurate imaging techniques to guide preoperative decision making
– How MSOT was used to identify lymphatic vessels and differentiate them from veins and arteries, including those at depth
– The outlook for MSOT to potentially aid clinicians in routine bedside detection of lymphatic vessels and utility in the lymphedema treatment process
This publication describes the details of the associated clinical trial: Guido Giacalone et al., Bedside 3D Visualization of Lymphatic Vessels with a Handheld Multispectral Optoacoustic Tomography Device. J Clin Med. 2020 Mar; 9(3): 815. https://www.mdpi.com/2077-0383/9/3/815.
Learn about MSOT’s optoacoustic phenomenon and its various applications. Register for the webinar here.
The clinical trial “Enhancing Ultrasound & Photoacoustic for Recognition of Intestinal Abnormalities (EUPHORIA)” is officially registered with clinicaltrials.gov as of July 2nd, 2020. Read the details here. There, you will find the study design, patient cohort information, the outcome measures and the eligibility criteria.
The clinical investigation aims to generate clinical data to support the use of Multispectral Optoacoustic Tomography (MSOT) in clinical practice, its inclusion in diagnostic guidelines and to support its reimbursement, specifically to
Further validate the application with respect to including ulcerative colitis patients
Prepare a study protocol for large-scale clinical validation study in inflammatory bowel disease (IBD)
Successfully execute the clinical validation study
Dr Dinish U. S and Dr Chris Ho of the Singapore Bioimaging Consortium (SBIC) will present on the use of Multispectral Optoacoustic Tomography (MSOT) to study morphological and functional changes associated with skin cancers in 2D and 3D. They will also describe the use of high-resolution Raster Scanning Optoacoustic Mesoscopy (RSOM) as an investigative tool for inflammatory skin conditions as well as the outlook for OAI to aid clinicians in the diagnosis and therapeutic monitoring of skin disease.
Both optoacoustic and optical imaging are biophotonic imaging technologies. While optoacoustic imaging yields information about light absorption from both endogenous tissue chromophores and optical contrast agents, optical imaging only provides information from extrinsically administered agents by means of light emission (fluorescence or bioluminescence). In terms of performance, optical imaging can serve as an easy-to-use screening tool with limited resolution and depth penetration, while optoacoustic imaging can probe biological questions in more detail and at greater depth. In this webinar, hear 10-minute presentations from three leading scientists who utilize both complementary imaging methods to study diseases on a molecular level, across three different applications:
Cancer: Judith Weber PhD, University of Cambridge
Inflammation: Alexa Hasenbach, University of Münster
Diabetes: Dr Sheryl Roberts, Memorial Sloan Kettering
iThera Medical’s upcoming webinar on May 20, 2020, will take place at 3:00 PM BST/ 4:00 PM CEST / 10:00 AM EDT. Sign up here.
The chat was hosted by Bruno Martin of ScienSeed, a partner on the New Deal, an EU Horizon 2020 funded project and one of EUPHORIA’s “Related Projects“. Joining Max and Bruno was Dr Azucena Salas, a researcher at IDIBAPS in Barcelona and principal investigator on the New Deal project, and Rachel Sawyer, a UK-based IBD patient advocate who manages the successful online Twitter stream, @bottomline_ibd.
The 50-minute chat focused on the state of the art and future prospects for IBD research, treatment and management. Watch it here!
Max remarked: “There is real value in communicating in a multi-disciplinary live forum such as this. It was a pleasure to be involved and to provide information about EUPHORIA with the public in this way. We will continue to share knowledge and build bridges with others working in research and patient advocates to improve IBD treatment.”
EUPHORIA coordinators at iThera Medical Gmbhhave produced a short explainer film to showcase the emerging diagnostic imaging technology, Multispectral Optoacoustic Tomography or MSOT for monitoring and managing inflammatory bowel disease. Watch it here https://youtu.be/dk8ioq9oG6I
Since 2010, iThera Medical has been selling successfully worldwide into the pre-clinical research imaging market. iThera Medical has established a global distribution network for its pre-clinical systems. EUPHORIA is a key enabling step for iThera to enter the clinical imaging market.
iThera Medical has a highly experienced team of currently 34 employees with expertise covering all aspects of optoacoustic technology, e.g., laser physics and fiberoptic light guides, data acquisition electronics, ultrasound detector design, and general electronic, electrical and mechanical capabilities.
EUPHORIA has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 830965. The material presented and views expressed here are the responsibility of the author(s) only. The EU Commission takes no responsibility for any use made of the information set out.
The EUPHORIA team enjoyed a very productive meeting in Besancon, France last week. The meeting ran over 2 days (23 and 24 January 2020) and all the partners were represented.
Researchers presented updates on all workstreams. IMASONIC and iThera outlined the significant progress made on improving the probe and transducer for the MSOT device. Final testing of the prototypes will be completed shortly and the choice of the transducer for use in the trial will be confirmed. Testing to date shows significant improvements. Software tasks in WP3 (led by Rayfos) are also well advanced.
Now that the EUPHORIA study protocol is near-final, work in WP4 by iThera and UK Erlangen is focused on preparations for the trial and obtaining ethical approval. Plans were discussed for a study workshop with the Advisory Board in February.
Preliminary work on certification of the device has already commenced in WP5 and dissemination and communication activities continue, with the new project video due for release shortly.
By the end of the meeting, the partners had agreed to a plan for the busy months ahead. Many thanks to our hosts in IMASONIC for a very fruitful and enjoyable event!
Third Party Embeds
Necessary cookies help make a website usable by enabling basic functions. The website cannot function properly without these cookies. You may disable these by changing your browser settings but this will affect how the website functions.